
In a groundbreaking LeoDOR trial, the efficacy and safety of intermittent levosimendan therapy following acute heart failure (HF) hospitalization were explored. Results showed that intermittent levosimendan had no significant impact on the primary endpoint compared to a placebo group, with mean rank scores of 72.55 vs. 73.81 (p=0.863). While no substantial improvement was observed in clinical stability, there were hints of increased risk in the levosimendan group for individual clinical components of the primary endpoint at both 14 and 26 weeks. This study could reshape post-HF patient care.
Like
Save
Share